|
|
| | BIBF 1120-13C-d3 Basic information |
| Product Name: | BIBF 1120-13C-d3 | | Synonyms: | BIBF 1120-13C-d3 | | CAS: | | | MF: | C31H30D3N5O4 | | MW: | 543.652305334 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | BIBF 1120-13C-d3 Chemical Properties |
| solubility | DMSO: 25 mg/ml |
| | BIBF 1120-13C-d3 Usage And Synthesis |
| Description | BIBF 1120-13C-d3 is intended for use as an internal standard for the quantification of BIBF 1120 (Item Nos. 11022 | 31082) by GC- or LC-MS. BIBF 1120 is an inhibitor of the receptor tyrosine kinases VEGFR, FGFR, and PDGFR (IC50s = 13-34, 37-610, 59, and 65 nM for VEGFR1-3, FGFR1-4, PDGFRα, and PDGFRβ, respectively).1 It is selective for VEGFR, FGFR, and PDGFR over a panel of 33 kinases but does inhibit FLT3, LCK, LYN, and Src (IC50s = 16-156 nM). BIBF 1120 inhibits growth factor-dependent proliferation of human umbilical vascular endothelial cells (HUVECs), human microvascular skin endothelial cells (HSMECs), human umbilical artery smooth muscle cells (HUASMCs), and bovine retinal pericytes (BRPs; EC50s = 7-290 nM). In vivo, BIBF 1120 (100 mg/kg) reduces tumor microvessel density and the number of PDGFRβ-expressing perivascular cells in a FaDu head and neck small cell carcinoma mouse xenograft model. It also inhibits tumor growth in a Caki-1 renal cancer mouse xenograft model. Formulations containing BIBF 1120 have been used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer (NSCLC).WARNING This product is not for human or veterinary use. | | References | [1] FRANK HILBERG. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.[J]. Cancer research, 2008, 68 12: 4774-4782. DOI: 10.1158/0008-5472.can-07-6307 |
| | BIBF 1120-13C-d3 Preparation Products And Raw materials |
|